SCHEMBL4429130

SCHEMBL4429130

COc1ccccc1C(=O)Nc1ccc(F)cc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.71
RAB9A P51151 4/20 0.71
ALDH1A1 P00352 2/20 0.71
KCNK3 O14649 3/20 0.69
KCNK9 Q9NPC2 3/20 0.69
SMN1; SMN2 Q16637 4/20 0.68
TP53 P04637 2/20 0.68
NPC1 O15118 2/20 0.68
MAPK1 P28482 2/20 0.68
KMT2A Q03164 5/20 0.67
GAA P10253 1/20 0.66
LMNA P02545 2/20 0.66
MEN1 O00255 2/20 0.64
POLB P06746 2/20 0.64
KDM4E B2RXH2 1/20 0.63
AHR P35869 1/20 0.63
GFER P55789 1/20 0.63
RECQL P46063 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739719 1.00 MAPT (0.71) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL2721612 0.89 MAPT (0.73) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL2362772 0.88 KMT2A (0.82) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL5390989 0.87 MAPT (0.71) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL3949532 0.87 KMT2A (0.78) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL4429129 0.86 MAPT (0.69) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL6294966 0.86 PNLIP (0.70) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL678394 0.86 MAPT (0.69) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL94630 0.86 MAPT (0.69) MAPTRAB9AALDH1A1KCNK3KCNK9
SCHEMBL4432153 0.86 MAPT (0.69) MAPTRAB9AALDH1A1KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12269814-B2 Process for preparing a compound useful to treat mycoses PULMOCIDE LIMITED (GB) 2025-04-08 US disclosed
US-11661415-B2 Process for preparing a compound useful to treat mycoses PULMOCIDE LIMITED (GB) 2023-05-30 US disclosed
US-9447027-B2 Treating long QT syndrome THE GENERAL HOSPITAL CORPORATION (US) 2016-09-20 US disclosed
US-9447027-B2 Treating long QT syndrome THE GENERAL HOSPITAL CORPORATION (US) 2016-09-20 US disclosed
CN-102827025-B 2-methoxy-N-(4-fluorophenyl) benzamide as well as preparation method and application of 2-methoxy-N-(4-fluorophenyl) benzamide UNIV XIHUA 2014-12-24 CN disclosed
CN-102827025-B 2-methoxy-N-(4-fluorophenyl) benzamide as well as preparation method and application of 2-methoxy-N-(4-fluorophenyl) benzamide UNIV XIHUA 2014-12-24 CN disclosed
US-20130310351-A1 Treating Long QT Syndrome THE GENERAL HOSPITAL CORPORATION (US) 2013-11-21 US disclosed
CN-102827025-A 2-methoxy-N-(4-fluorophenyl) benzamide as well as preparation method and application of 2-methoxy-N-(4-fluorophenyl) benzamide UNIV XIHUA 2012-12-19 CN disclosed
CN-102827025-A 2-methoxy-N-(4-fluorophenyl) benzamide as well as preparation method and application of 2-methoxy-N-(4-fluorophenyl) benzamide UNIV XIHUA 2012-12-19 CN disclosed
WO-2012054718-A2 TREATING LONG QT SYNDROME THE GENERAL HOSPITAL CORPORATION (US) 2012-04-26 WO disclosed
US-6897316-B2 Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents CHINA MEDICAL UNIVERSITY (TW) 2005-05-24 US disclosed
US-20050032832-A1 Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents CHINA MEDICAL UNIVERSITY (TW) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310351-A1 Treating Long QT Syndrome TNNI3, TNNT2, TNNC1 MAPT 3780/4885RAB9A 1007/4885ALDH1A1 3093/4885
US-20050032832-A1 Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHUK MAPT 4128/4885RAB9A 1223/4885ALDH1A1 465/4885
US-11661415-B2 Process for preparing a compound useful to treat mycoses DPM1, CYP51A1, ERG28 MAPT 2626/4885RAB9A 1450/4885ALDH1A1 2345/4885
US-12269814-B2 Process for preparing a compound useful to treat mycoses C1R, CBR1, CBR3 MAPT 4726/4885RAB9A 1340/4885ALDH1A1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.